Hospitalized COVID-19 patients with severe acute respiratory syndrome: A population-based registry analysis to assess clinical findings, pharmacological treatment and survival

2026-04-26T20:01:06Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/618772024-12-16T07:27:16Zcom_10324_1133com_10324_931com_10324_894col_10324_1209

Hospitalized COVID-19 patients with severe acute respiratory syndrome: A population-based registry analysis to assess clinical findings, pharmacological treatment and survival Gutiérrez Abejón, Eduardo Herrera Gómez, Francisco Magno Pedrosa Naudín, M. Aránzazu Tamayo Gómez, Eduardo Álvarez González, Francisco Javier SARS-CoV-2 COVID-19 SARS (Disease) Syndromes Clinical findings Pharmacotherapy Survival Supervivencia Virology Producción Científica Background and Objectives: One of the most serious clinical outcomes in hospitalized patients with COVID-19 is severe acute respiratory syndrome (SARS). The aim is to analyze pharmacological treatment, survival and the main mortality predictors. Materials and Methods: A real-world data study from COVID-19-hospitalized patients with SARS from 1 March to 31 May 2020 has been carried out. Variables such as hospital length of stay, ventilation type and clinical outcomes have been taken into account. Results: In Castile and Leon, 14.03% of the 7307 in-hospital COVID-19 patients developed SARS, with a mortality rate of 42.53%. SARS prevalence was doubled in males compared to females, and 78.54% had an age of 65 years or more. The most commonly used medicines were antibiotics (89.27%), antimalarials (68.1%) and corticosteroids (55.9%). Survival of patients developing SARS was lower compared to patients without this complication (12 vs. 13 days). The main death predictors were disseminated intravascular coagulation (DIC) (OR: 13.87) and age (>65 years) (OR: 7.35). Conclusions: Patients older than 65 years who develop DIC have a higher probability of hospital death. Tocilizumab and steroids have been linked to a lower incidence of hospital death, being the main treatment for COVID-19 hospitalized patients with SARS. 2023-10-04 2023-10-04 2022 info:eu-repo/semantics/article Medicina, 2022, Vol. 58, Nº. 6, 829 1648-9144 https://uvadoc.uva.es/handle/10324/61877 10.3390/medicina58060829 829 6 Medicina 58 1648-9144 eng https://www.mdpi.com/1648-9144/58/6/829 info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ © 2022 The Authors Atribución 4.0 Internacional MDPI